# In This Issue

Spring, 2026


- *Portfolio Additions*
- *Memberships*
- *Entrepreneur Presentations*
- *2026 1Q Activities*
- *Portfolio Highlights*
- *Sponsors*


# Chemical Angel Network

Funding and Supporting Hard-Tech Startups

## Recent Portfolio Additions

***Persperion Diagnostics*** aims to reimagine personalized health management using natural fingertip sweat. As a spinoff from UC San Diego in 2022, the company developed an enzymatic electrochemical test strip to directly sense different biomarkers within the natural fingertip perspiration. As the first step, it developed a first-of-its-kind noninvasive glucose monitor that allows people with diabetes to check their glucose levels accurately, easily, and affordably.

***Corveus Medical*** is developing a catheter-based solution that provides instant relief from the symptoms of chronic heart failure. Heart failure affects over 6M Americans, and hospitalizations contribute to a mounting cost burden on the healthcare system. Corveus' device performs a unique, targeted nerve ablation to inactivate a nerve branch, which has been shown in several publications to provide significant benefit for class III heart failure patients.

## Become a Chemical Angel

The Chemical Angel Network serves the accredited angel investor community by sourcing and presenting quality investment opportunities. Our mission is to provide financial capital and experienced mentorship to seed stage companies that have a strong chemical focus in Hard Tech, specifically in Measurements, Manufacturing, and Materials. These include Green Chemistry and Health Tech.

As a member you benefit from:

1. High-quality and Targeted Deal Flow.
2. Due Diligence and Deep Dives.
3. Deal Flow Management.
4. Weekly Remote Engagements.
6. Investing.

Become a network member by joining at: ***www.chemicalangels.com/investors.***

***Please reach out to an existing member or at*** membership@chemicalangels.com *if you are interested in attending a pitch session as a guest or have any questions.*

## Entrepreneur Presentations

The Chemical Angel Network is the only national angel network providing capital and expertise to early stage hard science ventures with a chemical component to the value proposition.

APPLY FOR FUNDING: Use the Chemical Angel Network website at ***http://chemicalangels.com/*** and select the Submit for Funding option. You will be invited to give a 5 minute presentation at our Introductory Pitch sessions. This is a portal to Gust, an online investment platform which we use for deal flow management. Selected companies will be invited to give a 30 min. presentation, including Q&A, at our session two weeks later.

Submit application at: ***www.chemicalangels.com/entrepreneurs***

## 2026 1Q Activities

**Introductory Pitch Sessions - January, February and March.**

**27** physical science based deals and 30 life science based deals were presented.

**12 Full Presentations -** These companies address the following markets and products.

Diagnostic platform delivering quantitative results.

Non-invasive sweat test strip for accurate and affordable glucose testing.

Software-driven precision 3D imaging.

Unique BODA chemistry platform for cost-effective production of semi-graphitic carbon monoliths and composites.

Extraction of diesel that is trapped in drill cuttings.

Fully circular, high-performance copper inks recovered from printed circuit boards.

Minimally invasive device that mimics open-heart tricuspid valve repair.

Redefining care for flea- and tick-borne diseases.

Next-gen, high-precision crop inputs to transform agriculture.

Low cost hydrogen production and usage to decarbonize trucking and industry.

Redefining minimally invasive surgery with fiber optic shape sensing.

Fixing the root cause of BPH (enlarged prostate) without surgery, implants, or sexual risk.

## Portfolio Highlights

**Johnson & Johnson** has entered into a definitive agreement to acquire ***Atraverse Medical, Inc.***, a privately-held medical device company pioneering next-generation left-heart access and radiofrequency (RF) technology.

***PanTher Therapeutics*** recently secured Series A Extension funding from SideCar Angels for their polymer-based platform delivering high-dose chemotherapy directly and continuously to solid tumors.

***AvantGuard*** has secured a $2M Phase IIB grant from the NIH to advance polyvantoin chlorine, our polymer-based disinfectant designed to combat antimicrobial-resistant biofilms in healthcare environments.

***Atticus Pharma***, a Zylö spinout with exclusive pharma rights to Zylö's patented Z-pod(R) sustained-release delivery technology (from Einstein College of Medicine), announces promising results in a clinical study involving 98 Subjects with androgenic alopecia. Lots of new-hair growth, with no adverse events.

***Leaven*** **Food's** All Purpose Instant Sourdough is a 2026 Nexty Award finalist at this year's Natural Products Expo.

***Aevumed*****'s** PROTEKT™, a Tenodesis Push-In Anchor, has received U.S. Food and Drug Administration (FDA) clearance, marking an important milestone in its clinical readiness.

***Axio BioPharma*** has been selected as a Round 1 awardee of the Innovation to Commercialization Pipeline (ICP) program, led by Forward BIOLABS.

***NatureWorks*** has now become the world's leading producer of polylactic acid (PLA) biopolymers, since launching the first commercial-scale PLA production in 2002.

## Sponsors

TOK TOKYO OHKA KOGYO AMERICA, INC.

DOW®

Frost Brown Todd ATTORNEYS

GC VENTURES AMERICA

Schrödinger